Clinical Trials Directory

Trials / Terminated

TerminatedNCT00440934

A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma

Étude de Phase II Pour déterminer l'efficacité Des Ondes électromagnétiques de Basse intensité administrées Par Voie Buccale Dans le Traitement du Cancer du Foie avancé

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Pasche, Boris, M.D. · Individual
Sex
All
Age
18 Years – 95 Years
Healthy volunteers
Accepted

Summary

Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year. The prognosis of patients suffering from advanced hepatocarcinoma is poor with an average survival of less than six months. Phase I data suggest that low levels of electromagnetic fields administered intrabucally with a portable and programmable device are a safe and potentially effective treatment for advanced cancer. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced HCC and limited therapeutic options will be offered treatment with a combination of frequencies.

Detailed description

Hepatocarcinoma (HCC) is the first cause of deaths due to cancer worldwide. More than one million two hundred thousand new patients are diagnosed each year. The prognosis of patients suffering from advanced hepatocarcinoma is poor with an average survival of less than six months. Therapies for hepatocarcinoma are limited. Resection of the primary tumor is the therapeutic approach of first choice when possible. Although this intervention results in long-term survival for some patients, only a minority of them are surgical candidates because of limitations due to tumor size, patient's overall condition or presence of hepatic cirrhosis. Phase I data suggest that low levels of amplitude-modulated electromagnetic fields administered intrabucally with a portable and programmable device are a safe and potentially effective treatment for advanced cancer. The device is connected to a spoon-like coupler placed in the patient's mouth during treatment. Patients with advanced HCC and limited therapeutic options will be offered treatment with a combination of HCC-specific frequencies. The patients will be offered ambulatory treatment, which will be administered three times a day for 60 min until disease progression or death.

Conditions

Interventions

TypeNameDescription
DEVICEAmplitude-modulated electromagnetic fields

Timeline

Start date
2007-02-01
Primary completion
2007-12-01
Completion
2007-12-01
First posted
2007-02-27
Last updated
2008-05-06

Locations

1 site across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT00440934. Inclusion in this directory is not an endorsement.